Ferenidou F, Mourikis I, Sotiropoulou P, Vaidakis N
Outpatient Clinic for Psychosexual Disorders, 1st Department of Psychiatry, University of Athens Medical School, Eginition Hospital, Greece.
Psychiatriki. 2019 Oct-Dec;30(4):339-344. doi: 10.22365/jpsych.2019.304.339.
The present paper is describing a case of persistent genital arousal disorder that developed to a 55-year-old woman, shortly after the initiation of zolpidem. Persistent genital arousal disorder (PGAD) is a clinical entity that appears with a relatively low frequency in women, and is characterized by persistent or recurrent, unwanted and bothersome feelings of genital arousal, which often do not resolve with orgasm and are not associated with sexual desire (sexual interest, thoughts or fantasies). Women who experience PGAD often have feelings of shame, guilt and distress. Although its exact etiology remains unclear, various etiological factors have been proposed, central or peripheral, which may be psychological, vascular, dietary, pharmacological or neurological. Additionally, its presence has been associated to restless legs syndrome and overactive bladder syndrome. Likewise, multiple therapeutic interventions have been proposed and tried in patients with PGAD, either pharmacological (SSRIs, SNRIs, antiandrogens, benzodiazepines, antipsychotics, anticonvulsive agents) or other (ECT, physiotherapy, psychotherapy, nerve stimulation). Zolpidem is a nonbenzodiazepine indirect GABA A receptor agonist, which has lately been used as a therapeutic agent for PGAD in some cases. Nevertheless, in our patient, receiving zolpidem for insomnia seemed to be timely connected to the onset of PGAD symptomatology. The aim of the present paper is to highlight the need for more research into the possible factors that may contribute to PGAD.
本文描述了一名55岁女性在开始服用唑吡坦后不久出现持续性性唤起障碍的病例。持续性性唤起障碍(PGAD)是一种在女性中出现频率相对较低的临床病症,其特征是持续性或反复性、 unwanted且烦人的生殖器唤起感觉,这种感觉通常不会因性高潮而缓解,且与性欲(性兴趣、想法或幻想)无关。经历PGAD的女性常常会感到羞耻、内疚和痛苦。尽管其确切病因尚不清楚,但已提出了各种病因因素,包括中枢或外周因素,可能是心理、血管、饮食、药理或神经方面的。此外,它的存在与不安腿综合征和膀胱过度活动症有关。同样,针对PGAD患者也提出并尝试了多种治疗干预措施,包括药理治疗(选择性5-羟色胺再摄取抑制剂、5-羟色胺-去甲肾上腺素再摄取抑制剂、抗雄激素、苯二氮䓬类、抗精神病药物、抗惊厥药物)或其他治疗(电休克治疗、物理治疗、心理治疗、神经刺激)。唑吡坦是一种非苯二氮䓬类间接GABA A受体激动剂,最近在某些情况下被用作PGAD的治疗药物。然而,在我们的患者中,因失眠服用唑吡坦似乎与PGAD症状的出现及时相关。本文的目的是强调需要对可能导致PGAD的因素进行更多研究。